1.
J Fam Pract
; 64(10): 610-23, 2015 Oct.
Article
in English
| MEDLINE
| ID: mdl-26551477
Subject(s)
Adrenergic beta-2 Receptor Agonists/pharmacology , Evidence-Based Medicine/methods , Pulmonary Disease, Chronic Obstructive , Respiratory System Agents , Disease Progression , Humans , Medication Therapy Management , Practice Guidelines as Topic , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory System Agents/classification , Respiratory System Agents/therapeutic use , Risk Assessment , Severity of Illness Index
2.
Hosp Pharm
; 49(6): 539-43, 2014 Jun.
Article
in English
| MEDLINE
| ID: mdl-24958971
ABSTRACT
Bupivacaine liposomal injection was recently approved by the US Food and Drug Administration (FDA) as a local anesthetic for use in management of postsurgical pain in adults. When compared to placebo, bupivacaine liposomal decreases postoperative pain and opioid use. This review examines the efficacy of bupivacaine liposomal when compared to conventional bupivacaine ± epinephrine using published and unpublished data provided to the FDA by the manufacturer.
